Research Reports

Summary

Certara reported Q1 2026 revenue of $106.9 million, up 1% YoY, completed $85 million divestiture of medical writing business to Veristat, and updated full-year 2026 guidance to $395-$405 million.

Key takeaways

Q1 2026 revenue $106.9M (+1% YoY); software +7%, services -4%.
Net loss $8.8M vs net income $4.7M YoY; Adjusted EBITDA $31.7M (-9%).
Sold medical writing business to Veristat for $85M cash + $15M escrow + up to $35M earn-out.
Updated 2026 revenue guidance $395M-$405M (0-4% growth ex-divested business).
Software bookings +20% YoY to $48.7M on strong demand.
Services bookings -14% YoY due to contract timing.